Patricia Habdas
Family · Pittsburgh, PANPI 1063959245
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $64,084 of the $82,505 with a category attached, or 77.7%. 16 manufacturers reported payments, led by AbbVie at 46.6% of the total. Reporting peaked in 2021 at $43,192 and has fallen 84.2% since, to $6,808 in 2025. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 378 payments — averaging $218.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$38K
- Biohaven Pharmaceuticals, Inc.$15K
- Biohaven Pharmaceutical Holding Company Ltd.$7K
- Lundbeck LLC$7K
- Lilly USA, LLC$5K
- Teva Pharmaceuticals USA, Inc.$4K
- plus $6K from 10 others
What the payments were for
- Consulting fees$2,4533%
- Speaking & faculty fees$64,08478%
- Travel & lodging$1,9392%
- Food & beverage$14,02317%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 195 | $38,422 |
| Biohaven Pharmaceuticals, Inc. | 42 | $14,753 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $7,433 |
| Lundbeck LLC | 16 | $6,872 |
| Lilly USA, LLC | 25 | $5,097 |
| Teva Pharmaceuticals USA, Inc. | 16 | $4,411 |
| Axsome Therapeutics, Inc. | 5 | $2,311 |
| Pfizer | 52 | $2,046 |
| Grifols USA, LLC | 2 | $310 |
| Impel Pharmaceuticals Inc. | 3 | $269 |
| EMD Serono, Inc. | 3 | $259 |
| SK Life Science, Inc. | 1 | $123 |
| Biogen | 1 | $100 |
| Avanir Pharmaceuticals, Inc. | 1 | $63 |
| Novartis | 1 | $22 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$82,505 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 94 | $159,501 |
| Nurtec OdtRimegepant Sulfate | 108 | $135,674 |
| Emgality PenGalcanezumab-Gnlm | 55 | $39,749 |
| QuliptaAtogepant | 29 | $33,882 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 27 | $21,688 |
| Aimovig AutoinjectorErenumab-Aooe | 28 | $20,389 |
| Ajovy SyringeFremanezumab-Vfrm | 23 | $16,427 |
| ReyvowLasmiditan Succinate | 13 | $10,313 |
| Oxcarbazepine | 27 | $1,678 |
| Prochlorperazine Maleate | 140 | $1,526 |
| Topiramate | 144 | $909 |
| Amitriptyline Hcl | 48 | $502 |
| Zonisamide | 13 | $423 |
| Gabapentin | 27 | $250 |
| Lamotrigine | 30 | $173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $38,422 | $193,383123 claims |
| PfizerNurtec Odt | $2,046 | $135,674108 claims |
| Lilly USA, LLCReyvow | $5,097 | $10,31313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Pittsburgh
- Kathleen ScholzPittsburgh$397K
- Kweilynn GreenePittsburgh$139K
- Margaret RosenzweigPittsburgh$89K
- Morgan ColePittsburgh$41K
- Amber GrinnellPittsburgh$33K
- Matthew BarnesPittsburgh$25K
- Alexander TatangeloPittsburgh$20K
- Sydney MurrayPittsburgh$19K
- Renee ConnPittsburgh$15K
- Shannon FitzgeraldAllison Park$370K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.